Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

Overview

The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli. The current IDSA guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the first line agents. However, over use of this empiric regimen could result in in appropriate treatment of bacteremia.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: June 2017

Detailed Description

The following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.

Clinical Trial Outcome Measures

Primary Measures

  • dead or alive
    • Time Frame: end of study
    • health status

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical information is collected by chart review of "case" and "control" patients. A "case" patient is defined as follows: – One or more blood cultures are positive for Gram-negative bacteria. – The same organism is recovered in urine culture within a 48-hour period. – The organism is ciprofloxacin resistant. – A "control" patient is defined as follows: – One or more blood cultures are positive for Gram-negative bacteria. – The same organism is recovered in urine culture within a 48-hour period. – The organism is ciprofloxacin susceptible. Exclusion Criteria:

  • negative culture

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Pittsburgh
  • Collaborator
    • Japan Health Sciences Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yohei Doi, MD, Principal Investigator, University of Pittsburgh

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.